Loading…
Dangerous Synthetic Drug Control Act of 2016
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
Dangerous Synthetic Drug Control Act of 2016 This bill amends the Controlled Substances Act to add certain synthetic opioids, hallucinogens, and cannabinoids to schedule I. (A schedule I controlled substance is a drug, substance, or chemical that: has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.)
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2016 · fourth_quarter · Health Issues
H.R.5926/S.3040, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations, FY2017, provisions relating to NIH and drug abuse and treatment Biomedical innovation legislation (Senate draft) H.R.6, 21st Century Cures Act, Medical research issues. H.R.34, 21st Century Cures Act, Medical research issues. Drug abuse research and treatment related issues: H.R.3537, Synthetic Drug Control Act of 2015 Public Law 114-198, Comprehensive Addiction and Recovery Act of 2016 S.3224/H.R.5934, Dangerous Synthetic Drug Control Act of 2016 S.36/H.R.4229, Protecting Our Youth from Dangerous Synthetic Drugs Act of 2015
Read twice and referred to the Committee on the Judiciary.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2016 · fourth_quarter · Science/Technology
HR. 8 North American Energy Security and Infrastructure Act H.R. 1806 America COMPETES Act Reauthorization Act H.R. 3537 Synthetic Drug Control Act H.R. 4783 Commercializing on Small Business Innovation Act H.R. 4909 National Defense Authorization Act H.R. 5583 University Regulation Streamlining and Harmonization Act S. 185 Promise for Antibiotics and Therapeutics for Health Act S. 771 Manufacturing Universities Act S. 2012 Energy Policy and Modernization Act S. 2089 American Energy Innovation Act S. 2658 Federal Aviation Administration (FAA) Modernization Act S. 2713 Advancing Precision Medicine Act of 2016 S. 2742 Promoting Biomedical Research and Public Health for Patients Act S. 2745 Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2793 SBIR/STTR Reauthorization Act S. 2812 SBIR and STTR Reauthorization and Improvement Act S. 2898 Small Business National Security Innovation Act S. 2943 National Defense Authorization Act S. 3084, American Innovation and Competitiveness Act S. 3224 Synthetic Drug Control Act S. 3346 The NASA Transition Authorization Act -- regarding research-related funding and policy issues affecting higher education institutions
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Science/Technology
HR. 8 North American Energy Security and Infrastructure Act H.R. 1806 America COMPETES Act Reauthorization Act H.R. 3537 Synthetic Drug Control Act H.R. 4783 Commercializing on Small Business Innovation Act H.R. 4909 National Defense Authorization Act H.R. 5583 University Regulation Streamlining and Harmonization Act S. 3346 The NASA Transition Authorization Act S. 185 Promise for Antibiotics and Therapeutics for Health Act S. 771 Manufacturing Universities Act S. 2012 Energy Policy and Modernization Act S. 2089 American Energy Innovation Act S. 2658 Federal Aviation Administration (FAA) Modernization Act S. 2713 Advancing Precision Medicine Act of 2016 S. 2742 Promoting Biomedical Research and Public Health for Patients Act S. 2745 Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2793 SBIR/STTR Reauthorization Act S. 2812 SBIR and STTR Reauthorization and Improvement Act S. 2898 Small Business National Security Innovation Act S. 2943 National Defense Authorization Act S. 3084 American Innovation and Competitiveness Act S. 3224 Synthetic Drug Control Act -- regarding research-related funding and policy issues affecting higher education institutions
Client expense: $15,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Science/Technology
HR. 8 North American Energy Security and Infrastructure Act H.R. 1806 America COMPETES Act Reauthorization Act H.R. 3537 Synthetic Drug Control Act H.R. 4783 Commercializing on Small Business Innovation Act H.R. 4909 National Defense Authorization Act H.R. 5583 University Regulation Streamlining and Harmonization Act S. 3346 The NASA Transition Authorization Act S. 185 Promise for Antibiotics and Therapeutics for Health Act S. 771 Manufacturing Universities Act S. 2012 Energy Policy and Modernization Act S. 2089 American Energy Innovation Act S. 2658 Federal Aviation Administration (FAA) Modernization Act S. 2713 Advancing Precision Medicine Act of 2016 S. 2742 Promoting Biomedical Research and Public Health for Patients Act S. 2745 Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2793 SBIR/STTR Reauthorization Act S. 2812 SBIR and STTR Reauthorization and Improvement Act S. 2898 Small Business National Security Innovation Act S. 2943 National Defense Authorization Act S. 3084, American Innovation and Competitiveness Act S. 3224 Synthetic Drug Control Act -- regarding research-related funding and policy issues affecting higher education institutions
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
H.R.5926/S.3040, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations, FY2017, provisions relating to NIH and drug abuse and treatment Biomedical innovation legislation (Senate draft) H.R.6, 21st Century Cures Act, Medical research issues. Drug abuse research and treatment related issues: H.R.3537, Synthetic Drug Control Act of 2015 H.R.2536/S.1455, Recovery Enhancement for Addiction Treatment Act TREAT Act Public Law 114-198, Comprehensive Addiction and Recovery Act of 2016 S.2423/H.R.4447, Opioid and Heroin Epidemic Emergency Supplemental Appropriations Act S.3224/H.R.5934, Dangerous Synthetic Drug Control Act of 2016 S.36/H.R.4229, Protecting Our Youth from Dangerous Synthetic Drugs Act of 2015
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
| Republican |
| TX |